-

GE HealthCare to Announce Fourth Quarter and Full Year 2022 Results on January 30, 2023

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will announce its fourth quarter and full year 2022 financial results before the market opens on Monday, January 30, 2023. The GE HealthCare management team will also host a conference call and webcast at 8:00 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay will also all be posted at the same link on the GE HealthCare Investor Relations website.

About GE HealthCare

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from prevention and screening, to diagnosis, treatment, therapy, and monitoring. We are an $18 billion business with 51,000 employees working to create a world where healthcare has no limits.

Contacts

GE HealthCare Investor Contact
Carolynne Borders
631.662.4317
carolynne.borders@gehealthcare.com

GE HealthCare Media Contact
Tor Constantino
585.441.1658
tor.constantino@gehealthcare.com

GE HealthCare

NASDAQ:GEHC

Release Versions

Contacts

GE HealthCare Investor Contact
Carolynne Borders
631.662.4317
carolynne.borders@gehealthcare.com

GE HealthCare Media Contact
Tor Constantino
585.441.1658
tor.constantino@gehealthcare.com

More News From GE HealthCare

GE HealthCare achieves MRI portfolio milestone with FDA clearances for next-generation SIGNA MRI technology designed to enhance precision imaging and clinical efficiency

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced today 510(k) clearance of three new magnetic resonance (MR) innovations with the U.S. Food and Drug Administration (FDA): SIGNA™ Sprint with Freelium™1, a 1.5T sealed magnet MRI system; SIGNA™ Bolt2, an advanced 3T MRI scanner; and SIGNA™ One3, an AI-driven ecosystem of workflow solutions designed to help reduce inefficiencies and support MRI exams from plan to scan and beyond. The new MRI systems and technology combat some of the...

GE HealthCare builds on BARDA collaboration with approximately $35 million expansion to advance artificial intelligence-powered ultrasound for trauma care and emergency preparedness

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a new approximately $35 million expansion to a previous contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The expansion is structured as a cost-share between BARDA and GE HealthCare, with BARDA providing the majority of funding. This jointly funded expanded a...

GE HealthCare announces cash dividend for first quarter of 2026

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2026 payable on May 15, 2026, to all shareholders of record as of April 3, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle...
Back to Newsroom